

**PRESS RELEASE**

07 February 2023 13:00:00 CET



## Lipum to participate in following upcoming events

**Lipum (publ), a clinical stage biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation in the following upcoming events.**

**BIO-Europe Spring** | March 20–22, 2023 | Basel, Switzerland

**LSX World Congress** | May 3-4, 2023 | London, UK

**Redeye Investor Forum** | May 11, 2023 | Malmö, Sweden

**BioStock Life Science Summit Spring** | May 30-31, 2023 | Digital

**BIO International Convention** | June 5-8, 2023 | Boston, MA, USA

“Our phase 1 clinical study on the lead candidate SOL-116 is ongoing and industry meetings provide opportunities to maintain our contacts and present the progress”, says CEO Einar Pontén.

### Contacts

Einar Pontén, CEO

E-post: [einar.ponten@lipum.se](mailto:einar.ponten@lipum.se)

Mobile: +46 70 578 34 95

Web: [www.lipum.se](http://www.lipum.se)

### About Us

Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company’s share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

### Attachments

[Lipum to participate in following upcoming events](#)